Planned Solutions Inc. Invests $206,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Planned Solutions Inc. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 234 shares of the biopharmaceutical company’s stock, valued at approximately $206,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Meyer Handelman Co. lifted its holdings in shares of Regeneron Pharmaceuticals by 11.4% in the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after acquiring an additional 435 shares during the last quarter. Stifel Financial Corp raised its holdings in Regeneron Pharmaceuticals by 12.2% in the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after buying an additional 3,385 shares during the last quarter. LPL Financial LLC raised its holdings in Regeneron Pharmaceuticals by 9.3% in the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after buying an additional 3,479 shares during the last quarter. Cavalier Investments LLC raised its holdings in Regeneron Pharmaceuticals by 88.6% in the 3rd quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock valued at $3,651,000 after buying an additional 2,084 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in Regeneron Pharmaceuticals by 32.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after buying an additional 1,221 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $966.30 on Thursday. The firm has a market cap of $106.06 billion, a P/E ratio of 27.81, a PEG ratio of 2.77 and a beta of 0.11. The firm has a 50-day moving average of $957.54 and a 200 day moving average of $878.93. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business earned $10.96 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.75 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock worth $13,124,641 over the last quarter. 8.83% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have issued reports on REGN shares. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the stock an “outperform” rating in a report on Wednesday, December 6th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 5th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Finally, Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $967.59.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.